Spyre Therapeutics at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Spyre Therapeutics takes part in 2 sessions at ACT 2026 in San Antonio. Its program centres on half-life-extended monoclonal antibodies, testing the toxicity of combining antibodies against α4β7, TL1A and IL-23. It also argues for a weight-of-evidence approach in place of an enhanced pre- and postnatal development study for its anti-IL-23 antibody.

OrganizationACT 2026 Attendance
spyre.com
Biotech companies
Clinical-stage biotech developing half-life-extended antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated diseases.
Poster
Mon Nov 16
5:00pm–6:30pm
Combination Toxicity Assessments of SPY001, SPY002, and SPY003, Half-Life Extended Monoclonal Antibodies Targeting α4β7, TL1A, and IL-23 (P121)
Nelson Exhibit Ballroom · Poster P121
Biologics and new modalities
Poster
Mon Nov 16
5:00pm–6:30pm

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Spyre Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction